TY - JOUR
T1 - Optimizing systemic therapy selection in metastatic colorectal cancer
AU - Grothey, Axel
PY - 2015/5/1
Y1 - 2015/5/1
N2 - For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.
AB - For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.
UR - http://www.scopus.com/inward/record.url?scp=84996522101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996522101&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0203
DO - 10.6004/jnccn.2015.0203
M3 - Article
C2 - 25995430
AN - SCOPUS:84996522101
SN - 1540-1405
VL - 13
SP - 682
EP - 685
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -